<DOC>
	<DOCNO>NCT01317108</DOCNO>
	<brief_summary>Chemo-N0 ( 1993-1998 ) first prospective randomize multicenter trial N0 BC design prospectively evaluate clinical utility biomarker . It use uPA/PAI 1 stratification criterion randomize high-risk patient chemotherapy versus observation ; low-risk patient remain without systemic therapy . The trial design answer two principle question : 1 . Can report prognostic impact uPA PAI 1 validate prospective multicenter therapy trial ? Does low uPA/PAI 1 identify low-risk N0 patient candidate spar necessity burden adjuvant chemotherapy ? 2 . Do uPA/PAI 1 high-risk patient benefit adjuvant CMF chemotherapy ?</brief_summary>
	<brief_title>Prognostic Predictive Impact uPA/PAI-1</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>N0 breast cancer patient tumor size &gt; /= 1 &lt; /= 5 cm diameter undergo standard locoregional treatment M1 status</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
	<keyword>node-negative</keyword>
</DOC>